查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1833557

2032 年神經系統疾病數位生物標記市場預測：按類型、適應症、臨床用途、最終用戶和地區進行的全球分析

Digital Biomarkers for Neurological Conditions Market Forecasts to 2032 - Global Analysis By Type (Wearable Devices, Mobile Applications, Sensors and Software Platforms), Indication, Clinical Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經系統疾病數位生物標記市場預計在 2025 年達到 8.949 億美元，到 2032 年將達到 46.386 億美元，預測期內的複合年成長率為 26.5%。

神經系統疾病的數位生物標記是透過穿戴式感測器、行動應用程式和植入式技術等數位裝置收集的客觀、可量化的生理和行為數據。這些生物標記物可以捕捉運動、認知、言語、睡眠和其他神經功能的變化，從而能夠持續監測疾病進展、治療反應，並早期發現帕金森氏症、阿茲海默症和多發性硬化症等神經系統疾病。透過整合進階分析和人工智慧，數位生物標記物可以提供個人洞察，支援臨床決策，並促進遠端患者管理。

神經系統疾病盛行率上升

老年人和高風險族群的神經退化性疾病正日益激發人們對非侵入性追蹤工具的興趣。行動感測器、穿戴式裝置和人工智慧平台正在將診斷能力擴展到傳統臨床環境之外。遠端監控和遠端醫療的整合正在推動整個醫療保健系統的採用。研究機構和醫療技術創新者正在推動即時神經系統數據收集。這些趨勢預計將顯著推動神經系統疾病數位生物標記物市場的發展。

缺乏標準化和檢驗

碎片化的通訊協定和不一致的資料流程限制了跨平台相容性。有限的基準測試限制了多中心試驗，並延緩了全球推廣。醫療保健提供者面臨著將多樣化資料流整合到現有系統中的挑戰。開發人員必須投資協調框架和強大的檢驗流程，以克服這些障礙。這些限制預計將限制神經系統疾病數位生物標記物市場的發展。

轉向個人化和預防性醫療保健

個人化認知和運動症狀追蹤正在重塑病人參與。與行動應用程式、雲端平台和穿戴式感測器的整合正在加速臨床和消費者層面的採用。公共衛生舉措和雇主健康計畫正在推動認知和運動監測工具的早期採用。對預防性腦健康管理的需求正在推動自適應生物標記系統的創新。這些趨勢預計將顯著推動神經系統疾病數位生物標記市場的發展。

開發和實施成本高

資金和技術需求限制了新興企業的進入。專用硬體、資料基礎架構和合規性要求降低了可負擔性並減緩了部署速度。臨床檢驗和縱向研究需要大量投資和營運能力。規模較小的公司在獲得報銷和機構合作方面面臨障礙。這些限制預計將阻礙神經系統疾病數位生物標記物市場的發展。

COVID-19的影響：

新冠疫情擾亂了臨床試驗，並減緩了數位生物標記物技術在神經系統護理領域的部署。遠端監控的需求和虛擬診斷的應用加速了人們對基於感測器的神經追蹤技術的興趣。在疫情封鎖期間，穿戴式裝置和行動平台因監測認知和運動症狀而變得流行。混合護理模式和遠距神經病學正在擴大疫情後數位生物標記工具的可及性。公共衛生部門對心理韌性和長期神經系統影響的關注，正在推動對可擴展解決方案的投資。這些轉變預計將推動神經系統疾病數位生物標記物市場的發展。

穿戴式裝置市場預計將成為預測期內最大的市場

由於神經系統疾病盛行率的上升以及對持續真實世界數據收集的需求，預計穿戴式設備領域將在預測期內佔據最大的市場佔有率。智慧型手錶、生物感測器和運動追蹤器正在推動臨床和消費者的採用。在醫院、研究中心和家庭護理環境中，運動功能、睡眠和認知監測的應用日益增加。與人工智慧分析和雲端平台的整合正在促進即時決策支援。製造商正在投資於能夠應對多種情況的多功能性和方便用戶使用型格式。預計該領域將顯著推動神經系統疾病數位生物標記市場的發展。

帕金森氏症領域預計將在預測期內以最高的複合年成長率成長

預計帕金森氏症領域將在預測期內實現最高成長率，推動對精準運動和認知追蹤的需求。數位生物標記有助於帕金森氏症的早期診斷、症狀進展監測和治療最佳化。穿戴式裝置、語音分析和步態感測器正在加速臨床研究和患者參與。與遠端醫療平台和個人化治療模式的整合正在推動其應用。開發人員正專注於擴充性且有效的工具，以滿足帕金森氏症的特定需求。預計該領域將推動神經系統疾病數位生物標記物市場的發展。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於神經系統疾病負擔的增加和區域創新。快速的都市化、人口老化以及不斷擴展的數位健康基礎設施正在推動需求。中國、印度、日本和韓國正在擴大神經復健和認知健康計畫。本地生產和具有競爭力的價格正在推動這些項目的採用。政府在精神健康和老年護理方面的支持措施正在推動市場擴張。這些趨勢預計將顯著推動亞太地區神經系統疾病數位生物標記市場的發展。

複合年成長率最高的地區：

在預測期內，北美預計將見證最高的複合年成長率，這得益於神經系統疾病的日益普及以及對腦健康創新的強勁投資。美國和加拿大正在將數位生物標記整合到臨床試驗、遠端醫療和個人化神經病學平台。學術機構和新興企業正在推動非侵入性追蹤和人工智慧主導分析領域的創新。監管部門對數位健康技術的支持正在加速市場滲透。官民合作關係和報銷範圍的擴大正在推動整個醫療保健系統的採用。這些發展預計將推動北美神經系統疾病數位生物標記物市場的發展。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章神經系統疾病數位生物標記市場（按類型）

  • 穿戴式裝置
    • 智慧型手錶
    • 健身追蹤器
    • 生物感測器
  • 行動應用程式
  • 感應器
    • 腦波感測器
    • 心電圖感測器
    • 動作感測器
  • 軟體平台
    • 數據分析工具
    • 雲端基礎的平台

第6章神經系統疾病數位生物標記市場（按適應症）

  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 癲癇
  • 其他適應症

7. 神經系統疾病數位生物標記市場（依臨床應用）

  • 診斷生物標記
  • 生物標記監測
    • 疾病進展追蹤
    • 治療反應評估
  • 預測性生物標記
    • 風險評估模型
    • 預後指標

8. 全球神經系統疾病數位生物標記市場（按最終用戶）

  • 醫療保健提供者
    • 醫院
    • 神經科診所
  • 醫療保健公司
    • 製藥公司
    • 生技公司
  • 研究機構
    • 學術機構
    • 臨床研究所

9. 全球神經系統疾病數位生物標記市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • NeuraLight
  • MindMaze SA
  • Neuroelectrics
  • Emotiv Inc.
  • NeuroPace, Inc.
  • Kernel
  • Cognifit Inc.
  • Posit Science Corporation
  • OpenBCI
  • Flow Neuroscience
  • BrainCo, Inc.
  • Novela Neurotechnologies
  • BioSensics LLC
  • Aural Analytics, Inc.
  • Quantified Health
Product Code: SMRC31390

According to Stratistics MRC, the Global Digital Biomarkers for Neurological Conditions Market is accounted for $894.9 million in 2025 and is expected to reach $4638.6 million by 2032 growing at a CAGR of 26.5% during the forecast period. Digital biomarkers for neurological conditions are objective, quantifiable physiological and behavioral data collected through digital devices such as wearable sensors, mobile apps, or implantable technologies. These biomarkers capture changes in movement, cognition, speech, sleep, and other neurological functions, enabling continuous monitoring of disease progression, treatment response, and early detection of neurological disorders like Parkinson's, Alzheimer's, and multiple sclerosis. By integrating advanced analytics and artificial intelligence, digital biomarkers provide personalized insights, support clinical decision-making, and facilitate remote patient management, improving outcomes while reducing reliance on traditional, episodic clinical assessments.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

Neurodegenerative conditions across aging and at-risk populations are accelerating interest in non-invasive tracking tools. Mobile sensors, wearables, and AI-powered platforms are expanding diagnostic capabilities beyond traditional clinical settings. Integration with remote monitoring and telemedicine is fostering adoption across healthcare systems. Research institutions and medtech innovators are propelling real-time neurological data capture. These dynamics are expected to significantly boost the digital biomarkers for neurological conditions market.

Restraint:

Lack of standardization and validation

Fragmented protocols and inconsistent data pipelines limit cross-platform compatibility. Limited benchmarking is constraining multi-center trials and slowing global deployment. Healthcare providers face challenges in integrating diverse data streams into existing systems. Developers must invest in harmonization frameworks and robust validation pipelines to overcome these barriers. These limitations are expected to constrain the digital biomarkers for neurological conditions market.

Opportunity:

Shift toward personalized and preventive healthcare

Individualized tracking of cognitive and motor symptoms is reshaping patient engagement. Integration with mobile apps, cloud platforms, and wearable sensors is accelerating uptake in both clinical and consumer settings. Public health initiatives and employer wellness programs are fostering early adoption of cognitive and motor monitoring tools. Demand for proactive brain health management is propelling innovation in adaptive biomarker systems. These trends are expected to significantly boost the digital biomarkers for neurological conditions market.

Threat:

High development and implementation costs

Financial and technical demands restrict entry for emerging players. Specialized hardware, data infrastructure, and compliance requirements are degrading affordability and slowing deployment. Clinical validation and longitudinal studies demand substantial investment and operational capacity. Smaller players face barriers in accessing reimbursement and institutional partnerships. Such constraints are expected to hinder the digital biomarkers for neurological conditions market.

Covid-19 Impact:

The Covid-19 pandemic disrupted clinical trials and delayed deployment of digital biomarker technologies across neurological care pathways. Remote monitoring demand and virtual diagnostics adoption accelerated interest in sensor-based neurological tracking. Wearables and mobile platforms gained traction during lockdowns for cognitive and motor symptom surveillance. Hybrid care models and tele-neurology are expanding access to digital biomarker tools post-pandemic. Public health focus on mental resilience and long-term neurological effects is fostering investment in scalable solutions. These shifts are expected to propel the digital biomarkers for neurological conditions market.

The wearable devices segment is expected to be the largest during the forecast period

The wearable devices segment is expected to account for the largest market share during the forecast period due to rising neurological disorder prevalence and demand for continuous, real-world data capture. Smartwatches, biosensors, and motion trackers are driving clinical and consumer adoption. Hospitals, research centres, and home-care settings are expanding use for motor function, sleep, and cognitive monitoring. Integration with AI analytics and cloud platforms is fostering real-time decision support. Manufacturers are investing in multi-condition versatility and user-friendly formats. This segment is expected to significantly boost the digital biomarkers for neurological conditions market.

The Parkinson's disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Parkinson's disease segment is predicted to witness the highest growth rate drives demand for precise motor and cognitive tracking. Digital biomarkers are enabling early diagnosis, symptom progression monitoring, and therapy optimization in Parkinson's care. Wearables, voice analytics, and gait sensors are accelerating clinical research and patient engagement. Integration with remote care platforms and personalized treatment models is fostering adoption. Developers are focusing on scalable, validated tools tailored to Parkinson's-specific needs. This segment is expected to propel the digital biomarkers for neurological conditions market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by rising neurological disease burden and regional innovation. Rapid urbanization, aging demographics, and expanding digital health infrastructure are accelerating demand. China, India, Japan, and South Korea are scaling neurorehabilitation and cognitive wellness programs. Local manufacturing and competitive pricing are fostering widespread adoption. Government-backed initiatives in mental health and aging care are propelling market expansion. These dynamics are expected to significantly boost the Asia Pacific digital biomarkers for neurological conditions market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR propelled by neurological disorder prevalence and strong investment in brain health innovation. United States and Canada are integrating digital biomarkers into clinical trials, remote care, and personalized neurology platforms. Academic institutions and startups are fostering innovation in non-invasive tracking and AI-driven analytics. Regulatory support for digital health technologies is accelerating market penetration. Public-private partnerships and reimbursement expansion are driving adoption across healthcare systems. These developments are expected to propel the North America digital biomarkers for neurological conditions market.

Key players in the market

Some of the key players in Digital Biomarkers for Neurological Conditions Market include NeuraLight, MindMaze SA, Neuroelectrics, Emotiv Inc., NeuroPace, Inc., Kernel, Cognifit Inc., Posit Science Corporation, OpenBCI, Flow Neuroscience, BrainCo, Inc., Novela Neurotechnologies, BioSensics LLC, Aural Analytics, Inc. and Quantified Health.

Key Developments:

In September 2025, NeuraLight partnered with the CHDI Foundation to develop precision eye movement biomarkers for Huntington's disease. This collaboration aims to create sensitive, trial-ready tools to support clinical trials and therapeutic development for Huntington's disease.

In July 2025, NeuroX acquired the assets and operations of MindMaze, a recognized leader in digital neurotherapeutics. This acquisition aimed to enhance NeuroX's capabilities in providing disease-modifying motor and cognitive treatments for neurological diseases and brain disorders.

Types Covered:

  • Wearable Devices
  • Mobile Applications
  • Sensors
  • Software Platforms
  • Data Analytics Tools
  • Cloud-Based Platforms

Indications Covered:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Other Indication

Clinical Applications Covered:

  • Diagnostic Biomarkers
  • Monitoring Biomarkers
  • Disease Progression Tracking
  • Treatment Response Assessment
  • Predictive Biomarkers
  • Risk Assessment Models
  • Prognostic Indicators

End Users Covered:

  • Healthcare Providers
  • Healthcare Companies
  • Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Biomarkers for Neurological Conditions Market, By Type

  • 5.1 Introduction
  • 5.2 Wearable Devices
    • 5.2.1 Smartwatches
    • 5.2.2 Fitness Trackers
    • 5.2.3 Biosensors
  • 5.3 Mobile Applications
  • 5.4 Sensors
    • 5.3.1 EEG Sensors
    • 5.3.2 ECG Sensors
    • 5.3.3 Motion Sensors
  • 5.5 Software Platforms
    • 5.5.1 Data Analytics Tools
    • 5.5.2 Cloud-Based Platforms

6 Global Digital Biomarkers for Neurological Conditions Market, By Indication

  • 6.1 Introduction
  • 6.2 Alzheimer's Disease
  • 6.3 Parkinson's Disease
  • 6.4 Multiple Sclerosis
  • 6.5 Epilepsy
  • 6.6 Other Indication

7 Global Digital Biomarkers for Neurological Conditions Market, By Clinical Application

  • 7.1 Introduction
  • 7.2 Diagnostic Biomarkers
  • 7.3 Monitoring Biomarkers
    • 7.3.1 Disease Progression Tracking
    • 7.3.2 Treatment Response Assessment
  • 7.4 Predictive Biomarkers
    • 7.4.1 Risk Assessment Models
    • 7.4.2 Prognostic Indicators

8 Global Digital Biomarkers for Neurological Conditions Market, By End User

  • 8.1 Introduction
  • 8.2 Healthcare Providers
    • 8.2.1 Hospitals
    • 8.2.2 Neurology Clinics
  • 8.3 Healthcare Companies
    • 8.3.1 Pharmaceutical Companies
    • 8.3.2 Biotech Firms
  • 8.4 Research Organizations
    • 8.4.1 Academic Institutions
    • 8.4.2 Clinical Research Organizations

9 Global Digital Biomarkers for Neurological Conditions Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 NeuraLight
  • 11.2 MindMaze SA
  • 11.3 Neuroelectrics
  • 11.4 Emotiv Inc.
  • 11.5 NeuroPace, Inc.
  • 11.6 Kernel
  • 11.7 Cognifit Inc.
  • 11.8 Posit Science Corporation
  • 11.9 OpenBCI
  • 11.10 Flow Neuroscience
  • 11.11 BrainCo, Inc.
  • 11.12 Novela Neurotechnologies
  • 11.13 BioSensics LLC
  • 11.14 Aural Analytics, Inc.
  • 11.15 Quantified Health

List of Tables

  • Table 1 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Wearable Devices (2024-2032) ($MN)
  • Table 4 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Smartwatches (2024-2032) ($MN)
  • Table 5 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Fitness Trackers (2024-2032) ($MN)
  • Table 6 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Biosensors (2024-2032) ($MN)
  • Table 7 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Mobile Applications (2024-2032) ($MN)
  • Table 8 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Sensors (2024-2032) ($MN)
  • Table 9 Global Digital Biomarkers for Neurological Conditions Market Outlook, By EEG Sensors (2024-2032) ($MN)
  • Table 10 Global Digital Biomarkers for Neurological Conditions Market Outlook, By ECG Sensors (2024-2032) ($MN)
  • Table 11 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Motion Sensors (2024-2032) ($MN)
  • Table 12 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Software Platforms (2024-2032) ($MN)
  • Table 13 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Data Analytics Tools (2024-2032) ($MN)
  • Table 14 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Cloud-Based Platforms (2024-2032) ($MN)
  • Table 15 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Indication (2024-2032) ($MN)
  • Table 16 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 17 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 18 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 19 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 20 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Other Indication (2024-2032) ($MN)
  • Table 21 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Clinical Application (2024-2032) ($MN)
  • Table 22 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Diagnostic Biomarkers (2024-2032) ($MN)
  • Table 23 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Monitoring Biomarkers (2024-2032) ($MN)
  • Table 24 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Disease Progression Tracking (2024-2032) ($MN)
  • Table 25 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Treatment Response Assessment (2024-2032) ($MN)
  • Table 26 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Predictive Biomarkers (2024-2032) ($MN)
  • Table 27 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Risk Assessment Models (2024-2032) ($MN)
  • Table 28 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Prognostic Indicators (2024-2032) ($MN)
  • Table 29 Global Digital Biomarkers for Neurological Conditions Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 31 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Neurology Clinics (2024-2032) ($MN)
  • Table 33 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Healthcare Companies (2024-2032) ($MN)
  • Table 34 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 35 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Biotech Firms (2024-2032) ($MN)
  • Table 36 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 37 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Academic Institutions (2024-2032) ($MN)
  • Table 38 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Clinical Research Organizations (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.